

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12Q 1/68, G01N 33/50	A1	(11) International Publication Number: WO 00/22168 (43) International Publication Date: 20 April 2000 (20.04.00)
(21) International Application Number: PCT/US99/23579 (22) International Filing Date: 12 October 1999 (12.10.99) (30) Priority Data: 09/170,640 13 October 1998 (13.10.98) US (71) Applicant: MA BIOSERVICES, INC. [US/US]; Life Sciences Center, 9900 Blackwell Road, Rockville, MD 20850-3349 (US). (72) Inventors: BIRD, Robert, Earl; 4620 Norbeck Road, Rockville, MD 20853 (US). GLEBOV, Oleg, K.; 12715 Sesame Seed Court, Germantown, MD 20874 (US). BORELLINI, Flavia; 940 Flying Fish Street, Foster City, CA 94404 (US). JACOBSON-KRAM, David; 5910 Chesterbrook Road, McLean, VA 22101 (US). OSTROVE, Jeffrey, M.; 1301 Tyrol Road, West Vancouver, British Columbia V7S 2L5 (CA). (74) Agents: MAYS, Thomas, D. et al.; Morrison & Foerster LLP, 2000 Pennsylvania Avenue, N.W., Washington, DC 20006-1888 (US).	(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: CARCINOGEN ASSAY (57) Abstract <p>The present invention is drawn to methods and assays for the early determination of whether a test agent is a carcinogen. These novel methods and assays are used to correlate the pattern of differential gene expression from mammalian cells treated with the test agent with reference patterns of differential gene expression of mammalian cells treated with known carcinogens. Further, the present invention is drawn to methods of use of DNA and RNA isolated from the treated mammalian cells as well as kits comprising same. The present invention also is drawn to methods of determining whether a test agent is a carcinogen by measuring protein synthesis or post-translational modifications from mammalian cells treated with the test agent compared with mammalian cells treated with a known carcinogen.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CARCINOGEN ASSAYTECHNICAL FIELD OF THE INVENTION

The present invention is drawn to the field of biotechnology and more
5 specifically to biomedical applications. Further, this invention relates to novel assays
for testing whether a compound is a carcinogen. Differential patterns of gene
expression for test chemical treated and untreated mammalian cells are compared to
those patterns established for known carcinogens.

10

BACKGROUND OF THE INVENTION

The current "gold standard" for testing whether a compound is carcinogenic is
performed with both sexes of two animal species that are treated chronically for two
years with a dose of compound at or near the maximum tolerated dose. The end point
of the assay is tumor formation. These assays are both expensive and laborious. The
15 aim of this invention is to greatly shorten the time required to determine whether a
chemical compound is a carcinogen.

Carcinogens act upon a cell in several ways, with the common result by
definition being induction of neoplasia or tumor formation. Carcinogens may be
chemical or biological agents. Chemical carcinogens include, for example,
20 compounds of: DMBA; benzo(a)pyrene; dibenzanthracene; acetoxymino fluorene,
methyl N. nitrosogreoxidine; nitroquinoline; dibromomethane; dibromoethane; furan;
and 12-O-tetradecanoyl-13-phorbol-acetate (TPA). Biological carcinogens include
oncogenic viruses, for example, such as members of the family of papilloma virus.
Chemical compounds and biological agents have the shared property that they are
25 each able to cause mutations of the genetic material of an animal cell or otherwise
alter the level of expression of non-mutated genes. Despite the different mechanisms
of action of carcinogens, these compounds each produce changes in gene expression
that occur in the transition from normal to tumor cell. Changes in the transcription
level may be detected by differential displays of mRNA isolated from a cell treated
30 with a carcinogen. The changes in the level of translation of the mRNA may also be

detected in the differential display of proteins or peptides synthesized in the treated cell.

Differential display of mRNA has been articulated as a means of evaluating the gene expression profile of a cell for the identification of cancer related genes and elucidation of their role in tumorigenesis. For example, more than 100 candidate tumor suppressor genes have been described. (Sager, R., *Proc. Natl. Acad. Sci. USA* (1997) 94:952-955). Some of these have been identified using differential display of cDNA prepared from isolated mRNA. While more than 100 oncogenes have been identified in animal cells, only a small subset have been found consistently as mutated genes in human cancer (Copper G. M. (1995) *Oncogenes*; Jones & Bartlett, Seedbury); Weinberg, R.A. *Sci. Am.* (1996) 275:62-70; and Bishop, J.M. *Cell* (1991) 64:235-248). The progression of neoplasia development and transformation into malignant tumors is not well understood. However, since cancer genes are defined by their phenotypic expression, research into their differential phenotypic expression has been undertaken as a means to further elucidate the process of carcinogenic induction of tumorigenesis.

For example, carcinogen-mediated changes in cell metabolism may differentially alter the expression of oncogenes, tumor suppressor genes, cell cycle regulators, DNA replication genes (e.g., encoding repair enzymes, receptors), growth factors, stress proteins or known tumor markers. Such differential gene expression may be represented by an increase or decrease of levels of expression or may result in modifications to the gene product expressed, that is, altered forms of proteins, which function differently than proteins in normal cells (e.g., greater or lesser binding affinity; requirement or lack of requirement of co-factors).

Many studies have addressed the changes in genes (mutations) and the changes in gene expression in tumors. These alterations in sequence and synthesis have also been examined as markers of tumorigenesis. However, no one has examined the early changes in gene expression in the first days or weeks after the beginning of treatment with a test compound to determine whether a subset of the changes that occur early in carcinogen treatment are useful to predict whether a tested compound is a carcinogen. The pattern that is developed need not be similar to that in the tumor but need only be predictive of tumorigenic potential.

Seven cDNA fragments of gene transcripts that were overexpressed in mammary carcinomas in the rat model induced by 1-methyl-1-nitrosourea have been identified by differential display of mRNA and molecular cloning (Lu, J., *et al.*, *Molecular Carcinogenesis* (1997) 20:204-215). However, this research involved the
5 comparison of the latter stage of tumorigenesis (2 months following chemical carcinogenic induction) with control mammary tissue. Lu *et al.* did not disclose any methods for the differential display of gene transcript fragments associated with the earlier stages of tumorigenesis, that is, prior to actual tumor formation.

Similarly, there are numerous reports in the literature of the identification and
10 role of various oncogenes and tumor suppressor genes. For example, the use of differential display to study gene expression during development of squamous cell carcinomas and the important role played by c-fos (or v-fos) in the transformation to the malignant phenotype in keratinocytes has been reported (Rutberg, S., *et al.*, *Molecular Carcinogenesis* (1997) 20:88-98). Rutberg *et al.*, as did Lu *et al.*, used
15 the latter stage endpoint of tumor formation in the comparison of differential gene expression in establishing the role of oncogene transformation of epithelial tissue.

There is a clear need for assays which predict at an early stage whether an unknown compound is a carcinogen. Current assays are designed to determine whether an agent is carcinogenic by using one or more surrogate markers. For
20 example, the widely used Ames test represents an analysis of the effects of a test compound upon the frequency of reverse mutation of bacterial test strains, such as the histidine auxotrophic strains of *Salmonella typhimurium* (*Manual of Methods for General Bacteriology*, Gerhardt et al, American Society for Microbiology Press, Washington, D.C. (1981) at page 237). This test is not absolute, since a compound
25 under this assay may be mutagenic and not be carcinogenic or alternatively a compound may not evidence mutagenicity in this assay but be carcinogenic as determined using other tests.

Current short-term assays are based mostly on correlation between mutagenic and carcinogenic potential of compound that was established in earlier studies. This
30 correlation is exploited directly in *Salmonella* mutation assay (Ames test), in the mouse *tk⁺* assay, and CHO *hprt* assay. There are also assays based on abilities of carcinogens to interact with DNA or chromatin directly, like DNA adducts assay and

single cell gel assay for DNA strand breaks. The mechanisms underlying other assays are less clearly defined, like for micronucleus assay, and cytogenetic assays (FISH, aneuploidy or sister chromatid exchange assays) but are thought to reflect at least in part, the disturbance of the DNA or chromosome organization. These assays show
5 good sensitivity for mutagenic carcinogens but as a rule cannot detect effectively activity of the nongenotoxic carcinogens.

Recently a new test, the Syrian Hamster Embryo (SHE) Cell Transformation assay was developed and refined, which is based on the ability of carcinogens to induce immortalization and transformation (morphological and malignant) of the SHE
10 cells in culture (Isfort and LeBoeuf, *Mutation Research* (1996) 365:161-173). This assay shows good sensitivity and accuracy for mutagenic carcinogens as well as nongenotoxic carcinogens.

Application of the battery of mentioned short-term tests increases the validity of prediction of whether compounds may be carcinogens. However, tumorigenic
15 transformation of a cell in an organism is a result of the complex interaction of the cells with a carcinogen (possibly metabolically activated) and with other cells of the organism. Hence, one should expect that cells may react to a tested compound depending on the cell's phenotypic characteristics, that is, for example, tissue-specific characteristics. Cells of different tissue-specific characteristics may react to the same
20 compound with different outcomes. Considering possible differences in cell response, the enormous variety of industrial, pharmacological, and therapeutic compounds that need to be tested, and further considering the multitude of activation pathways, there is a clear need for a short-term carcinogenicity assay that allows for the evaluation of a cell's response to a compound in different tissues of an organism.

25 Another more recent approach to assaying the effects of test compounds, at least indirectly upon a cell's genome, employs cells transfected with genetic constructs comprising selected "stress promoters" that are induced by specific stress factors, such as "DNA stress" which includes damage to DNA strands by chemicals or UVA radiation (Farr, S., *et al.*, EP 0 680 517 (1997)). In this assay, the transformed
30 cell is exposed to potentially toxic compounds and the levels of transcription of one or more heterologous reporter genes, each of which is operatively linked to its respective stress promoter, is assayed for transcription by hybridization of probes specific to the

mRNA of each reporter gene. This assay indirectly measures whether a potentially toxic compound will induce a stress promoter to permit transcription of its reporter gene. Farr *et al.* discloses the creation of a "stress induction profile" for each compound by classifying which stress promoters are induced for each compound tested. This method indirectly measures toxicity by the use of artificial gene constructs of selected "stress promoters" and selected reporter genes as they are transfected into specific host cells. Further, this method measures through hybridization whether an mRNA transcript of a reporter gene is expressed by a stress promoter that responds to toxic agents. Since the stress promoter is fused out of context to the reporter gene, this method does not measure the functionality of the transcript or translated protein product. Since Farr *et al.* transformed HepG2 cells in their assay, these artificial gene constructs may provide different outcomes if the constructs are used to transform different host cells or host cells of different tissues. Still wanting is a method that measures differential expression of native genes on a wider scale and in the short period following exposure of the target cell to the test compound.

The high-throughput methods (based mostly on using high-density gene arrays) developed in recent years, will be exploited to establish patterns of gene expression changes that are diagnostic for response to known carcinogens of the different mouse tissue cells. These patterns will serve as a basis for a new short-term assay for detecting carcinogenic potential of chemical and biological compounds.

A high-capacity quantitative method of differential gene expression that uses hybridizable cDNA arrays robotically printed on glass was reported by Schena, M., *et al.*, *Science* (1995) 270:467-470. This method fixes to a substrate amplified cDNA prepared from both complete gene sequences and from partial sequences or expressed sequence tags (ESTs). Fluorescent hybridization probes were prepared from total mRNA and used to identify corresponding cDNA. This methodology was able to clearly identify the overexpression of a single target gene.

In contrast, currently available assays for carcinogenesis either operate in bacterial test systems, which do not accurately reflect mammalian cellular response, or require a significant amount of time to demonstrate phenotypic expression of carcinogen activity in mammalian whole animal models. The present invention is

able to quickly identify carcinogen activity by effects upon differential gene expression in mammalian cells or animals at a point in time prior to tumor formation by comparing these differential levels of expression with prior determined patterns of differential genetic expression caused by known carcinogens.

5

SUMMARY OF THE INVENTION

The present invention provides an assay for the early detection of carcinogenesis by measuring the net changes in gene expression that result from the treatment of a mammalian cell or whole animal with a test agent over those of a control cell or control whole animal further compared with previously determined reference patterns of genetic expression altered by known carcinogens. The present invention further provides methods and kits to identify a carcinogen. The present invention also provides for methods for identifying DNA and proteins related to carcinogenesis. Additionally, the present invention contemplates the DNA and proteins related to carcinogenesis that are identified by the methods and assays of the present invention and that are predictive that a test agent or substance is a carcinogen.

More specifically, one embodiment of this present invention provides assays and methods comprising the steps of: a) preparing cDNA from RNA isolated from mammalian cells treated with a test agent for less than about two years, wherein said cDNA is detectably labeled; b) determining a pattern of expression by assessing the ability of said labeled cDNA to hybridize to each of a multiplicity of nucleotide sequences arrayed on a substrate; c) determining reference patterns of differential gene expression by assessing the ability of a second labeled cDNA to hybridize to each of a multiplicity of nucleotide sequences, wherein said second labeled cDNA is prepared from RNA isolated from mammalian cells treated with a known carcinogen for less than about two years; and d) comparing similarities in patterns of expression from cells treated with a test agent to reference patterns from cells treated with a known carcinogen.

A preferred embodiment provides that RNA is isolated from mammalian cells treated with a test agent or known carcinogen for less than about six months. A further preferred embodiment provides that RNA is isolated from mammalian cells treated less than about two weeks or more preferably treated for less than about two days.

In another preferred embodiment, the test cDNA may be labeled with a fluorescent molecule emitting one wavelength of light and the control cDNA labeled with a second fluorescent molecule emitting a second wavelength of light. The hybridization results that form a pattern of expression and clearly represent effects of treatment of mammalian cells with a test agent or substance will always thus be controlled internally. Other preferred embodiments include the use of other similarly detectable labels, that include but are not limited to: radioisotopes; enzymes; antigens or antibodies.

Another embodiment of the present invention is a method to identify a test substance as a carcinogen, which method includes: a) providing cDNA derived from mammalian cells that have been contacted with the test substance for less than about two years; b) determining a first pattern of hybridization of the cDNA with respect to a multiplicity of nucleotide sequences; and c) comparing the pattern with a corresponding second pattern obtained at a corresponding time after the cells have been contacted with a known carcinogen, whereby a similarity in the first and second patterns identifies the test substance as a carcinogen. A preferred embodiment provides that the cDNA is obtained from cells that have been contacted with the test substance or a known carcinogen for less than about six months. A further preferred embodiment provides that the cDNA is obtained from cells contacted for less than about two weeks or more preferably contacted for less than about two days.

Another aspect of the present invention provides an assay kit for identifying a test substance as a carcinogen, comprising: a) reagents for the preparation of cDNA prepared from RNA isolated from mammalian cells treated with a test substance for less than about two years; b) reagents for the preparation of cDNA prepared from RNA isolated from mammalian cells treated with a known carcinogen for less than about two years; c) DNA sequences arrayed on a substrate that are hybridizable to the cDNA; and d) label suitable for the detection of the DNA sequences hybridized to the cDNA; wherein the identification of a test substance as a carcinogen is achieved by creating a first pattern of differential gene expression using cDNA prepared from the RNA isolated from mammalian cells treated with a test substance for less than about two years and comparing the first pattern with a corresponding second pattern obtained at a corresponding time after the cells have been contacted with a known

carcinogen, whereby a similarity in the first and second patterns identifies the test substance as a carcinogen.

Yet another aspect of this invention provides an assay for early detection of carcinogenesis, comprising the steps of: a) selecting a protein isolated from
5 mammalian cells treated with a test agent for less than about two years; b) measuring differences in protein synthesis or post-translational modification; and c) determining whether the test agent is carcinogenic by comparing differences in protein synthesis or post-translational modification to protein isolated from mammalian cells treated with a known carcinogen for less than about two years. In a preferred embodiment, this
10 invention provides that the differences in protein synthesis or post-translational modification are measured by electrophoretic gel analysis and that the protein is detectably labeled. Such detectable labels, include but are not limited to: a fluorescent dye; radiolabelled compound; or enzymatically detectable label, for example, horse radish peroxidase or alkaline phosphatase.

15 One other embodiment of the present invention provides that differences in protein synthesis or post-translational modification are measured by enzymatic digestion of protein and mass spectrometry analysis.

In another embodiment, this invention contemplates that the mammalian cells are treated with a carcinogen *in vitro*. In still another embodiment, this invention
20 contemplates that the mammalian cells are treated with a carcinogen *in vivo*. Still another preferred embodiment, this invention provides that the differential gene expression is selected from the group consisting of genes whose level of expression is increased; genes whose level of expression is decreased; genes that are expressed and genes that are not expressed.

25 Another aspect of the present invention provides for methods of identifying genes, genetic sequences and proteins related to carcinogenesis as well as the genes, genetic sequences and proteins identified by the methods of this invention. A further aspect of the present invention provides for the reference patterns of differential gene expression of mammalian cells treated with a known carcinogen. Another
30 embodiment of the present invention provides for protein measure by any one of the methods disclosed. A still further aspect of the present invention includes DNA or a

DNA sequence as used in any of the methods provided herein, where the DNA or DNA sequence is predictive that a test agent or test substance is a carcinogen.

Additional aspects of the present invention relate to the use of substrates as contemplated herein. A preferred embodiment of the present invention provides for a multiplicity of nucleotide sequences arrayed on a substrate. A still further preferred
5 embodiment contemplates substrates selected from the group consisting of: membrane filter; glass; ceramic; and solid organic polymer.

The present invention further contemplates the use of one or more assays or methods as discussed *supra* and further disclosed herein used in combination with one
10 another. For example, a preferred embodiment includes the steps of: preparing a first cDNA from a first mRNA; isolated from mammalian cells treated with a test agent for less than about two years, wherein the first cDNA is detectably labeled; determining a pattern or expression by assessing the ability of the labeled cDNA to hybridize to each of a multiplicity of nucleotide sequences arrayed on a substrate; determining reference
15 patterns of differential gene expression by assessing the ability of a second labeled cDNA to hybridize to each of a multiplicity of nucleotide sequences, wherein the second labeled cDNA is prepared from a RNA isolated from mammalian cells treated with a known carcinogen for less than about two years and comparing similarities in patterns of expression from cells treated with a test agent to reference patterns from
20 cells treated with a known carcinogen. This assay further comprises the steps of: selecting a protein isolated from the same mammalian cells treated with the same test agent for less than about two years; measuring differences in protein synthesis or post-translational modification; and determining whether the test agent is carcinogenic by comparing differences in protein synthesis or post-translational modification to
25 protein isolated from mammalian cells treated with a known carcinogen for less than about two years. In a preferred embodiment, this invention provides that the differences in protein synthesis or post-translational modification are measured by electrophoretic gel analysis and that the protein is detectably labeled.

Citation of the above documents is not intended as an admission that any of
30 the foregoing is pertinent prior art. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or

contents of these documents. Further, all documents referred to throughout this application are incorporated in their entirety by reference herein.

BRIEF DESCRIPTION OF THE DRAWINGS

5 Figure 1 shows changes in gene expression in TPA-Treated and calcium differentiated mouse keratinocytes.

Figure 2 shows P & T Primers used in polymerase chain reaction.

DETAILED DESCRIPTION OF THE INVENTION

10 The above and various other objects and advantages of the present invention are achieved by preparing a differential display of genetic expression for cells treated with a test agent compared with reference patterns of differential gene expression of mammalian cells treated with one or more carcinogens.

 Unless defined otherwise, all technical and scientific terms used herein have
15 the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications and patent documents referenced in this application are incorporated in their entirety
20 herein by reference.

 For example, what is meant by carcinogenesis is the origin or initiation or production of neoplasia or tumor formation. Neoplasia is meant to include both benign and malignant growth of new tissue. Such neoplasia may include, but is not limited to: carcinoma, sarcoma, lymphoma, blastoma, and mesothelioma. A test agent
25 is any molecule, compound or biological organism that is selected to be used with the methods, assays or other embodiments of the present invention. The test agent may be modified or altered to facilitate carcinogenicity. Further, the use of the term carcinogen is intended to include carcinogenic agent. Mammalian cells include both cultured cell lines as well as cells isolated from mammalian tissues.

30 Conditions for the hybridization of DNA are readily available to one in the art. Such conditions include those as provided in Denhardt *et al.*, *J Mol Biol* 12(3):641-646 (1965) or in Dahlberg, *et al.*, (U.S. Patent 5,691,142), which is incorporated in its

entirety herein by reference. The detection of specific nucleic acid sequences or a multiplicity of nucleotide sequences as present in oligonucleotides has been achieved typically by hybridization. Hybridization methods involve the annealing of a complementary sequence to the target nucleic acid (the sequence to be detected). The ability of two polymers of nucleic acid containing complementary sequences to find each other and anneal through base pairing interaction is a well-recognized phenomenon. The initial observations of the "hybridization" process by Marmur and Lane, *Proc. Natl. Acad. Sci. USA* 46:453 (1960) and Doty et al., *Proc. Natl. Acad. Sci. USA* 46:461 (1960) have been followed by the refinement of this process into an essential tool of modern biology. Initial hybridization studies, such as those performed by Hayashi et al, *Proc. Natl. Acad. Sci. USA* 50:664 (1963), were formed in solution. Further development led to the immobilization of the target DNA or RNA on solid supports. With the discovery of specific restriction endonucleases by Smith and Wilcox, *J. Mol. Biol.* 51:379 (1970), it became possible to isolate discrete fragments of DNA. Utilization of immobilization techniques, such as those described by Southern, *J. Mol. Biol.* 98:503 (1975), in combination with restriction enzymes, has allowed for the identification by hybridization of single copy genes among a mass of fractionated, genomic DNA.

What is meant by differential gene expression is, for example, but is not limited to, a method to evaluate the expression of the genes of a cell. Such differential gene expression may be represented as an increase or decrease in the levels (including non-detectable levels) of transcription of genes by the synthesis of mRNA. Differential gene expression may also be represented as an increase or decrease in the levels (including non-detectable levels) of translation of mRNA coding for a gene in the synthesis of a protein or peptide. Also, differential gene expression may include post-translational modification of the protein or peptide sequence as well as mutated forms of the protein or peptide gene product.

What is meant by reference patterns of differential gene expression is the physical manifestations of differential gene expression. Such patterns may take the form of films or gels or data records or other tangible representations of hybridizations of genetic fragments or levels of protein or peptide synthesis that are

created by determining the changes in genetic expression of mammalian cells that have been treated with known carcinogens.

What is meant by referring to mammalian cells as pre-tumorous cells is that the cells have not yet demonstrated tumor formation or unregulated growth.

5

I. Differential Genetic Expression Array

The present invention contemplates that the reference patterns of differential gene expression of this assay could include as few as several sequences and up to thousands. The selection of genes may be made by simply choosing known
10 oncogenes, tumor suppressor genes, cell cycle regulation genes, and DNA replication genes (encoding repair enzymes, receptors) growth factor genes, stress proteins or known tumor marker genes. While one may determine to screen all known EST's in databases known to the art, it is more likely that sufficient sequences, to define a pattern or patterns of gene synthesis change, will be found by only screening a
15 fraction of the known sequences. It is not necessary to detect every change but rather to detect a number of changes that are sufficient to establish a reference pattern that is useful in distinguishing a carcinogen from other non-carcinogenic compounds. The number of sequences that are contemplated for selection may range between three to 1000 and preferably from 10 to 200 and more preferably from 20-100.

20 The present assay will detect changes in gene expression early in a treatment protocol. These changes may occur in subsequent tumors caused by the carcinogen but this is not a necessary finding. The important changes may be transitory and our experiments are designed to detect them. We anticipate that the important changes occur in treated animals from as few as a single treatment to five doses per week for
25 up to 90 days. We wish to shorten the time that animals are treated as much as possible.

Initially test cDNA is prepared from RNA obtained from tissue of animals treated with a test agent, where in order to create reference patterns, test agents will be carcinogens. The reference will be cDNA prepared from RNA of control animals of
30 the same age, sex, and protocol that have not been treated with a test agent but with the vehicle alone. An ideal version of the assay could be the selection of a set of cell

lines that show a pattern of gene synthesis, which is a diagnostic of a carcinogen. This would eliminate the use of animals completely for our assays.

II. Use of cDNA hybridization patterns

5 Once the set of gene sequences to be used in our tests has been selected we contemplate that assays may be performed using one of several formats. (1) Gene sequences to be tested could be immobilized on a substrate, such as silicon, glass or other suitable surface or sequences may be synthesized in place on the surface. Many such substrates are commonly referred to as chips or gene chips. The first cDNA
10 probe, labeled with one detectable label such as a fluorescent molecule, is prepared from RNA extracted from a tissue from a treated animal. The second cDNA probe prepared from RNA extracted from the same tissue from a matched control animal and labeled with a second detectable label, such as a second fluorescent molecule. These probes are hybridized to the cDNA or oligonucleotides on the chip. After
15 hybridization, the relative amount of the detectable labels, for example the fluorescence, is measured over each spot of cDNA and this measurement is corrected for housekeeping cDNA sequences on the same chip. Housekeeping cDNA sequences are used as a control to normalize data. The differences in synthesis, either increased or decreased relative to the control, define the pattern of synthesis or gene
20 expression. The observed pattern is compared to our database to determine whether it resembles a pattern associated with known carcinogens. Housekeeping genes are sequences such as β -actin cDNA because β -actin is assumed to be synthesized in both treated and untreated animals. We are not limited to β -actin as a control and can use any sequence, which is synthesized at the same levels in both tissues. Hybridization
25 results are internally controlled by labeling the test cDNA using one detectable label that is distinguishable over the second detectable label, for example, by labeling the test cDNA with a fluorescent molecule emitting one color of light and the control cDNA labeled with a second fluorescent molecule emitting a second distinguishable color.
30 (2) A second method would be to fix an array of cDNA on a glass slide or other ceramic substrate. The labeling, hybridization, and analysis are performed similarly to that described *supra* in order to determine the pattern of synthesis for a

sample. An array of DNA sequences could easily be prepared using techniques available to one of skill in the art. For example, U.S. Patent 5,445,934 teaches a method and apparatus for preparation of a substrate containing a plurality of sequences. Photoremovable groups are attached to a surface of a substrate. Selected regions of the substrate are exposed to light so as to activate the selected areas. A monomer, also containing a photoremovable group, is provided to the substrate to bind at the selected areas. The process is repeated using a variety of monomers such as amino acids until sequences of a desired length are obtained. Detection methods and apparatus are also disclosed. Also, U.S. Patent 5,700,637 teaches an apparatus and method for analyzing a polynucleotide sequence; either an unknown sequence or a known sequence. A support, e.g. a glass plate, carries an array of the whole or a chosen part of a complete set of oligonucleotides which are capable of taking part in hybridization reactions. The array may comprise one or more pair of oligonucleotides of chosen lengths. The polynucleotide sequence, or fragments thereof, are labeled and applied to the array under hybridizing conditions. Applications include analyses of known point mutations, genomic fingerprinting, linkage analysis, characterization of mRNAs, mRNA populations, and sequence determination.

A multiplicity of nucleotide sequences arrayed on a substrate may also be commercially available, for example, from Clontech Laboratories.

(3) A third method would be to denature and array the cDNA sequences for our set of test sequences on two sets of membrane filters. Radiolabeled cDNAs are prepared from the test RNA and the control and each is hybridized to a set of membrane filters. After washing, the filters are either exposed to x-ray film or analyzed in a phosphoimaging system to measure the amount of cDNA hybridized to each set of membranes. The hybridization is normalized for housekeeping genes and the pattern of synthesis determined by the relative radioactivity over each cDNA. This determination is made by comparing a test filter with its control counterpart. A further alternative is to employ two separate radioisotopes for labeling the cDNA prepared from test RNA and cDNA prepared from the control RNA.

The skilled artisan would readily appreciate from the present disclosure, that other detectable labels, including enzymes, such as horse radish peroxidase or alkaline phosphatase may be used accordingly.

III. Use of Protein Synthesis Patterns

The present invention further contemplates that the changes in translation of genetic sequences as well as the changes in transcription of genes, as has been discussed *supra*, may be used as a measure or characteristic of whether a test agent functions as a carcinogen. Changes in the amounts or levels of expression of the genetic end products -- proteins-- as translated from the mRNA of mammalian cells may also be determined. However, the present invention should not merely be limited to the detection of differences in the level of protein synthesis, either increased or decreased, in a tissue from treated animal cells since postranslational modification could also be affected by carcinogen treatment. These postranslational modifications include: cleavage of the protein into smaller units; degradation to short peptides or amino acids; phosphorylation; alkylation; deamidation; glycosylation; as well as any other postranslational modifications of the synthesized proteins.

The methods available to measure difference in protein synthesis or postranslational modifications are well known in the art. For example, two dimensional polyacrylamide gel electrophoresis separates proteins or peptides by net charge in the first direction and by size in the second. Proteins or peptides are visualized by staining or autoradiography and analyzed using image analysis software.

Proteins can be displayed by two-dimensional gel electrophoresis. A sample of protein to be displayed is loaded onto an isoelectric focusing gel and the proteins allowed to reach equilibrium. A lane of this gel, narrow strip, or tube gel is laid on top of an SDS Page slab gel and the proteins previously separated by isoelectric point now are separated by size. The proteins thus displayed can be detected by staining or by autoradiography if previously radiolabeled. Clearly the proteins displayed from any sample will depend on the sample preparation, pH range of the focusing gel, and the polyacrylamide concentration of the size separation gel.

The proteins differentially expressed early in test compound treatment can be identified by comparing two dimensional gels run on proteins extracts of tissues from treated and untreated animals. A protein that is overexpressed upon treatment will show up as a stronger spot on the treated gel and underexpressed proteins will be lighter than the corresponding control spot. The protein in question can be further

identified by trypsin (or other specific cleavage treatment) and analysis by mass spectrometry. The precise molecular weights of the peptides can be matched to peptide databases to make the identification. If one peptide appears in more than one protein, additional peptides can be analyzed to complete the identification.

5 An alternate method of analyzing proteins would be through the use of mass spectroscopy to characterize proteins or peptides by their mass. This characterization could be coupled to a method of separation of proteins, including capillary electrophoresis or liquid chromatography. The separation or filtration step or the two dimensional gells above, will limit the number of proteins or peptides characterized at
10 any one time. Furthermore, the filtering step may be designed to emphasize those proteins most changed by the treatment with a carcinogen. Identification would be made by searching a molecular weight database.

 Additional filtering steps could be followed in the method of initial extraction of the proteins or peptides. Rather than examining the total proteins synthesized in a
15 tissue, selected fractions could be analyzed. Such fractions may include: the isolation of soluble fractions; membrane fractions; salt precipitate fractions; or fractions obtained by any other treatment.

 Clearly the characterization of carcinogens by protein changes, either alterations in synthesis or modifications, will yield reference patterns of differential
20 genetic expression or changes that are characteristic of carcinogens. These reference patterns may characterize a new carcinogenic agent if the pattern resulted from treatment of animal cells with the new agent.

 Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of
25 illustration, and are not intended to be limiting of the present invention, unless specified.

EXAMPLE 1Gene Expression Changes in TPA-Treated and Terminally Differentiated Primary
Mouse Keratinocytes Cultures

1. Primary mouse keratinocytes cultures

5 Cultures of newborn mouse keratinocytes were established essentially as described by H. Hennings (In *Keratinocyte Methods*, Cambridge University Press (1994), pages 21-23). Briefly, mice two to three days postpartum were sacrificed by metaphane narcosis, rinsed in 70% ethanol, and kept on ice. Skins were peeled off, stretched out and floated (with epidermis facing upward) on the surface of a 0.25%
10 trypsin solution in Ca^{+2} , Mg^{+2} free PBS overnight at 4°C. Skins were transferred to a sterile surface, the epidermis was separated from dermis, the epidermis was minced, and the mixture stirred in serum-free keratinocyte growth medium (KGM, Clonetics). This cell suspension was filtered through nylon gauze, cells were centrifuged (2,000 rpm for 5 min), resuspended in KGM with 20 μM Ca^{+2} (20 KGM), and then the cells
15 were counted and plated (approximately 2×10^6 per 10 cm plate coated with mouse collagen type IV in 20 KGM) and the cell cultures were incubated at 37°C with a 7% CO_2 . After 16-24 hours, cells were washed in Ca^{+2} , Mg^{+2} free phosphate buffered saline (PBS), and cultivated on 20 KGM, with the cell culture medium changed (that is, old medium discarded and fresh medium provided) each other day. For induction
20 of terminal differentiation, medium was changed, usually on the sixth day of cultivation of the keratinocytes, to KGM containing 1.2 mM Ca^{+2} , and the keratinocytes were cultivated for 24 hours before RNA isolation.

For phorbol-myristate acetate (TPA) treatment, keratinocyte cultures were fed with 20 KGM containing 0.1 $\mu\text{g/ml}$ of 12-O-tetradecanoyl-13-phorbol-acetate for 24
25 hours, before isolation of RNA.

2. Differential display of mRNAs synthesized in control keratinocytes, Ca^{++} differentiated keratinocytes and TPA-treated keratinocytes.

Total RNA was isolated by acid phenol procedure using TRI Reagent™
30 (Molecular Research Center, Inc.) and according to manufacturer's instructions from (1) terminally differentiated keratinocytes, cultivated in KGM medium containing 1.2mM Ca^{+2} for 24 hours; (2) TPA-treated keratinocytes, cultivated in KGM

containing 20 μM Ca^{+2} and 0.1 $\mu\text{g/ml}$ TPA for 24 hours; and (3) control keratinocyte cultures fed 24 hours before RNA isolation with 20 KGM containing, in some experiments, 0.05% DMSO (dimethyl sulphoxide).

Differential display of total RNAs from keratinocyte cultures (1), (2), and (3) was performed with Delta-RNA Fingerprinting Kit™ (Clontech) according to the manufacturer's instructions. Briefly, cDNAs were synthesized from total RNAs using Murine Moloney Leukemia Virus (MMLV) reverse transcriptase. Two dilutions of cDNA were prepared (diluted 10-fold and 40-fold). Each total RNA sample was used to synthesize cDNA that was amplified using polymerase chain reaction (PCR) methodology using P & T primers in presence of [α - ^{33}P] dATP. These primers are listed in Figure 2. The labeled amplified bands were displayed on sequencing gels and the differential appearance of labeled bands for each primer pair was examined. The appearance of a band from a sample that was not present in the control lane indicated overexpression and the disappearance or reduction in intensity of a band indicated suppression of synthesis. The candidate bands were cut from the sequencing gel and reamplified using the original primer pairs. Following electrophoresis on agarose gels, reamplified DNA fragments were cut out and purified using a QIAEX II gel extraction kit™ (QIAGEN). The DNAs were labeled and used to confirm the differential expression by hybridization with Northern blots of Poly (A)⁺ containing RNA isolated from total RNAs (1),(2), and (3). Equal quantities of these RNAs were electrophoresed on agarose gels and blotted to nitrocellulose filters. Equal loading of RNA was confirmed by hybridization with a β -actin probe, whose mRNA was assumed to be present in approximately equal amounts in all of the preparations. The blots were stripped of radiolabel and then used to confirm the differential synthesis of a fragment. Upon confirmation, the fragment was cloned into pCRII using the TA cloning kit™ (Introvitrogen). Cloned DNA fragments were sequenced with SequiTerm Excel II kit™ (Epicentre Technology).

The genes or ESTs identified by differential display are presented in Table 1.

Table 1. Differentially Expressed Genes in TPA Treated Keratinocytes, Identified By Differential Display and Northern Blot Hybridization

Gene	Size of Cloned Fragment, bp	Changes in Expression (Comparative to Untreated cells)	Known Homologous Sequence
110176/4	200	Suppressed in TPA- Treated Cells	Mouse Cytokeratin Endo A (156/156;100%)
2672/1	550	Suppressed in TPA- Treated Cells	Mouse ESTs AA492919 (124/127;97%), AA607761 (93/97;95%); Human Dnase 1 Homologue HS U62647 (41/53;77%)
31777	650	Overexpressed in TPA- Treated Cells	Mouse EST AA073833 (67/67; 100%)
19102/3	320	Overexpressed in CA+2- Treated and Suppressed in TPA- Treated Cells	Mouse ESTs AA038613 (251/251;100%), W14382 (212/213; 99%)
3177715	650	Suppressed in TPA- Treated Cells	Mouse ESTs AA423711 ((156/156;100%), and AA637015 (96/98;97%)
83442	550	Overexpressed in TPA- Treated Cells	Mouse Connexin 26 (160/161; 99%)
31774/6/8	650	Suppressed in TPA- Treated Cells (6 kb RNA)	Mouse ESTs AA423711 (186/186;100%), W82493 (198/203;97%; and 52/53; 98%, AA63700159132/134;98%)
4314	1000	Overexpressed in TPA - and Ca+2- Treated Cells	AA109991(200/201;99%), AA561914(200/201;99%) AA067670 (139/140; 99%), AA864127 (133/134;99%)
2552/4	650	Suppressed in TPA- Treated Cells (5.5 kb RNA)	ND

- 5 3. Hybridization of cDNA to filters containing mouse DNA sequences
- Atlas™ Membranes (Clontech) contain mouse cDNA in paired spots. Each pair cDNA, included gene sequences from known oncogenes, tumor suppressors, cell cycle regulators, stress response genes, ion channels and transporters, intracellular signal transducers, apoptosis genes, DNA synthesis, DNA repair, DNA
- 10 recombination, transcription factors, general DNA binding proteins, receptors, cell surface antigens, cell adhesion, cell-cell communication, cytoskeleton, mobility, protein turnover, and housekeeping proteins. Each membrane filter contained 588-mouse cDNA's, as well as nine housekeeping control cDNAs, and negative control sequences. We have used pairs of these filters to select additional gene sequences,
- 15 which are differentially expressed in the keratinocytes.

Poly(A)⁺, containing RNAs were prepared from total RNAs isolated from control (untreated), TPA-treated and terminally differentiated primary mouse keratinocytes as discussed *supra*. Labeled cDNAs were synthesized with reagents provided in the Atlas™ Kit (Clontech) and used for hybridization with Atlas™
5 membranes (Clontech) according to manufacturer instructions. An experimental cDNA was always compared to control cDNA. The filters were washed and exposed to X-ray films for varying lengths of time. Estimation of equal hybridization to housekeeping genes was used as normalization so that gene sequences that are over or under-expressed could be determined by the difference in intensity of the same spots
10 on an experimental filter and a control.

Two and three technicians analyzed sets of radioautograms exposed to pairs of Atlas™ membranes (ClonTech) hybridized to experimental and control cDNAs and showing equal signals for housekeeping genes. Only genes that were consistently identified as overexpressed or suppressed genes comparing control radioautograms, as
15 shown in Figure 1, are provided in Tables 2 and 3.

**Table 2 Differentially Expressed Genes In TPA Treated Keratinocytes,
Identified by Hybridization With Atlas™ cDNA Array(s) (Membranes)**

Overexpressed Genes	Suppressed Genes
p53 protein	Tumor suppressor maspin
TSG101 tumor susceptibility protein	cErbA oncogene; Thyroid hormone receptor
RNA Polymerase I termination factor TTF-1	cJun proto-oncogene
Cot proto-oncogene	c-myc proto-oncogene
CSF-1; colony stimulating factor 1	IGFBP-2; insulin-like growth factor binding protein 2
Cdk4	p18inc4; cdk4 and cdk6 inhibitor
Oxidative stress-induced protein	Golgi 4 transmembrane spanning transporter
I-Kappa B alpha chain	Glucose transporter-1
Protein kinase C theta type	Interleukin-6 receptor beta chain
Transducin beta-2 subunit	STAT6; (IL-4 Stat)
Bax protein; homologue of Bcl-2	Syp; adaptor protein tyrosine phosphatase
GST Pii; glutathione S-transferase Pi 1	Gluthathione S-transferase (microsomal)
Chop 10; homologue of Gadd153	Gluthathione S-transferase Mul
TDAG51; couples TCR signaling to Fas expression	Protein tyrosine phosphatase
Activating transcription factor 4	Butyrate response factor 1
Homeo box protein 8	CACCC Box binding protein BKLF
CD44 antigen	DP-1 (DRTF- polypeptide 1) cell cycle regulatory transcription factor
Integrin alpha 2	HMG-14
Integrin beta	Dystroglycan 1
VLA-3 alpha subunit	Follistatin
Inhibin beta subunit	Cytokeratin 1
Cytokeratin 18	TIMP-3 tissue inhibitor of metalloproteinase 3
Cathepsin	

Table 3 Differentially Expressed Genes in Terminally Differentiated Keratinocytes Identified by Hybridization With Atlas™ cDNA Array Membranes

Overexpressed Genes	Suppressed Genes
Ezrin (Villin 2)	Tumor suppressor maspin
ZO-1 (Tight junction protein)	c-myc proto-oncogene
Cot proto-oncogene	Cyclin G
Casein kinase II (alpha Subunit)	Prothymosin alpha
N-ras proto-oncogene	BST-1; CD38 antigen
p18ink4; cdk4 and cdk6 inhibitor	GST Pi 1; glutathione S-transferase Pi 1 preadipocyte growth factor
Glutathione reductase	DAD-1; defender against cell death 1
CACCC Box- binding protein	SP13; serine proteinase inhibitor
Homeobox protein 8	MHR23B; Rad23 homologue
Retinoic acid binding protein II (CRABP-II)	Ubiquitin-conjugating enzyme
Insulin-like growth factor binding protein-1 (IGFBP-1)	YY1 (UCRBP) transcription factor
Cytokeratin 18	CD44 antigen
	Dystroglycan 1
	Neuroleukin
	Cytokeratin 14
	Cathepsin H
	Cathepsin L

5 4. cDNA subtraction and hybridization with Atlas™ membranes
(Clontech)

 cDNAs were synthesized from poly(A)⁺ RNA isolated from untreated control and TPA-treated mouse keratinocytes and subtracted using PCR-Select™ cDNA subtraction kit (Clontech) following by the manufactures instructions. cDNA from

10 TPA-treated keratinocytes that was subtracted against cDNA from untreated cells was labeled by random primer labeling protocol and used in hybridization studies on Atlas™ cDNA membranes. These studies identified genes that were overexpressed in TPA-treated keratinocytes. Similarly, cDNA from control keratinocytes was subtracted against cDNA from TPA-treated keratinocytes. Varying the time of film

15 exposure, normalized hybridization signals for housekeeping genes were obtained and autoradiograms were analyzed by two technicians. A list of genes overexpressed and suppressed upon TPA treatment of mouse primary keratinocytes is shown in Table 4.

Table 4 Differentially Expressed Genes in TPA Treated Keratinocytes Identified by Hybridization of the Subtracted cDNAs with Mouse Atlas™ cDNA Array Membranes

Overexpressed Genes	Suppressed Genes
BST-1; lymphocyte differentiation antigen CD38	c-ErbA oncogene (Thyroid hormone receptor)
I-Kappa B alpha chain	H-ras proto-oncogene
Rac 1 murine homologue	Cyclin D1
Zyxin; LIM domain protein;-actin binding protein	Cyclin D2
Bax protein (Bcl-2 homologue)	Prothymosin alpha
GST Pi 1; glutathione S-transferase; preadipocyte growth factor	Hsp27; heat shock 27KD- protein 1
c-Act proto0 oncogene; Rac-alpha; proteine kinase B	Dystroglycan 1
Nuclear factor related to p45 NF-E2	Insulin- like growth factor binding protein 6 (IGFBP 6)
Monocyte chemoattractant protein 3	TIMP-3 tissue inhiditor of metalloproteinases-3
Interleukin-2 receptor gamma chain	
CD18 antigen beta subunit	
CD44 antigen	
CD14 antigen	
Glutamate receptor channel subunit gamma	
Bone morphogenetic protein 1	
Macrophage inflammatory protein	
Macrophage inflammatory protein 1 (Act2)	
Macrophage inflammatory protein 2 alpha	
Interleukin 1Beta	
Cytokeratin 14	
Cytokeratin 1	
Cathepsin L	
Collagenase type IV	
Plasminogen activator inhibitor-2	
Serine protease inhbitor 2 (spi-2)	

5

EXAMPLE 2

Gene Expression Changes in Skin and Liver of DMBA-Treated Mice

1. Skin treatment of mice with DMBA

DMBA (7, 12-dimethyl benz[α] anthracene) is a potent carcinogen that causes tumor formation on the skins of C₃B₆F₁ mice in just over six months of chronic treatment. Because of its potency at causing tumors it was chosen as the first compound to test in animals for the change in pattern of gene expression following a short period, two weeks, of carcinogen treatment.

10

Approximately 5-sq. cm area was shaved on the backs of C₃B₆F₁ mice. Three males and three females were treated for ten weekdays with 250 µg of DMBA in 100 µl of acetone. Controls were treated with 100 µl acetone alone.

The next weekday following the tenth treatment, the animals were sacrificed
5 and the following tissues removed and flashed frozen in liquid nitrogen; treated skin, liver, bladder, lungs, and stomach.

2. Differential gene expression in mouse skin treated with DMBA

Since the treated tissue is the site of maximum tumor formation, this tissue
10 was examined first. Total RNA was extracted from skin by the Trizol acid phenol procedure after grinding the tissue to a powder in liquid nitrogen. PolyA RNA was isolated with oligotex mRNA kit™ (QIAGEN).

Radiolabeled cDNA was prepared from pooled DMBA treated skin PolyA⁺ RNA and from the pooled control PolyA⁺ RNA, as discussed *supra*. Approximately
15 equal amounts of each was hybridized to an Atlas™ membrane, the filter was washed, and exposed to X-ray film.

After development of several exposures the films were compared and a treated film and control film with approximately equal hybridization for the housekeeping genes were compared to determine which of the 588 mouse sequences on the filter are
20 overexpressed or underexpressed following treatment. Genes found to be overexpressed and suppressed in DMBA treated skin are presented in Table 5.

**Table 5 Differentially Expressed Genes in DMBA-Treated Mouse Skin
Identified by Hybridization with Mouse Atlas™ cDNA Array
Membranes**

Overexpressed Genes	Suppressed Genes
IGFBP-2; insulin-like growth factor binding protein 2	RNA polymerase I termination factor TTF-1
HSP84	ERp72; disulfide isomerase related protein
Cf2r; thrombin receptor	Etoposide induced p53 responsive (E124) mRNA
Inhibitor of the RNA-activated protein kinase	Grp78; glucose regulated protein
Lymphotoxin receptor	Glutathione S-transferase
Laminin receptor 1	Glutathione S-transferase Mu 1
snoN; ski-related oncogene	Butyrate response factor 1
Neuroleukin	Egr-1 Zn-finger protein
Placental Rnase inhibitor	HMG 14
Serine protease inhibitor 2 (spi-2)	Nuclear factor related to P45 NF-E2
	Split hand/foot gene
	Transcription factor S-II
	IGFBP-4; insulin-like growth factor binding protein 4
	Interleukin 15

5 Differential gene expression in DMBA-treated mouse skin was also probed by hybridization with Mouse Gene Discovery Arrays (GDA) (Genome Systems, Inc.) containing 18,378 double-spotted none-redundant mouse cDNA clones chosen from the I.M.A.G.E. collection. 2.5 µg of polyA⁺-RNA from DMBA-treated and control mouse skin was used for cDNA labeling and hybridization with two GDA membranes

10 according to the manufacturer instructions, and obtained PhosphorImager files were sent to and analyzed by Genome Systems, Inc. service. As shown in Table 6, 599 cDNA clones display 3 or more fold differences in expression in DMBA-treated skin compared to acetone-treated skin among clones with top 1000 scores (calculated by multiplying ratio of hybridization intensity on difference in average - for two spots -

15 hybridization intensity for corresponding cDNA clones; hybridization intensity for cDNA clones was normalized for intensity of hybridization of control DNA spots).

Table 6. Number of cDNA Clones with Changes in Expression in DMBA-Treated Mouse Skin

Difference in Expression	Number of Genes	
	Overexpressed	Suppressed
More than 3-fold	285	122
More than 5-fold	50	24
More than 9-fold	12	6

3. Differential gene expression in livers of DMBA treated mice

RNA was extracted from mouse liver, which had been previously ground into a fine powder in liquid nitrogen. Poly(A)⁺ RNA was prepared from total RNA and radiolabeled cDNA prepared, as discussed *supra*. The cDNAs from the liver of 2

- 5 control animal and a treated animal were each hybridized to an Atlas™ membrane and the differential pattern of gene expression deduced. While initially the filters showed little or no differential expression, upon more careful examination differential expression was observed indicating that the DMBA or a derivation of it had reached the liver and caused changes in gene expression. These results are presented in Table
- 10 7.

Table 7. Differentially Expressed Genes in Liver of DMBA-Treated Mice Identified by Hybridization With Mouse Atlas™ cDNA Array Membranes

Overexpressed Genes	Suppressed Genes
p53 protein	Cyclin A
Lfc proto-oncogene	Prothymosin alpha
CSF-1	Cf2r; coagulation factor II (thrombin) receptor
Cdk4	CRE-BP1; cAMP response element binding protein 1
Heat shock protein 84KD	Gluthathione S-transferase (microsomal)
Etoposide induced p53 responsive (E124) mRNA	Elf-1 Ets family transcription factor
I-Kappa Beta	HMG-14
SP13; serpin	HomeoBox protein 2.5
CACCC Box binding protein BKLF	Follistatin
Homeo box protein 8	Membrane type matrix metalloproteinase
Interleukin-2 receptor gamma chain	
Glucocorticoid receptor form A	
Bone morphogenetic protein 1	
Cathepsin D	
Cathepsin L	
Collagenase type IV	

15

EXAMPLE 3

Gene Expression Changes in Liver of Mice Treated with Furan and Trichloroethylene

1. Treatment of mice with Carcinogens.

Furan and trichloroethylene (TCE) are shown to induce hepatocellular carcinomas in mice; both are negative in *Salmonella* mutagenicity test though furan

induces gene mutations, and sister chromatide exchanges and chromosomal aberrations in mammalian cells in vitro. C₃B₆F₁ Mice were treated with either furan (30 mg/kg/dose) or TCE (2400 and 1800 mg/kg/dose for males and females respectively) by gavage in corn oil. The control mice were treated with corn oil alone.

- 5 The study contained ten animals of each sex in each treated and control group. The treatment was carried out for ten working days, with no treatment on weekend days for the carcinogen-treated animals and for nine days of control group. The treatment was carried out for ten working days, with no treatment on weekend days for the carcinogen-treated animals and for nine days for control group. Animals were
- 10 sacrificed humanely and tissues were snap-frozen in liquid nitrogen.

2. Differential gene expression in liver of mice treated with furan and TCE. Total and (polyA+)RNAs isolation, labeling of cDNA, hybridization with Atlas™ cDNA Expression Arrays (Clontech) and analysis of the hybridization results were performed as described above for differential gene expression in DMBA-treated
- 15 mouse skin. List of genes that showed changes in expression in liver of furan and TCE-treated mice is presented in Table 8.

Table 8
Differentially Expressed Genes in Liver of Mice Treated with Furan and Trichloroethylene

Overexpressed Genes		Suppressed Genes	
Furan Treated Liver	TCA Treated Liver	Furan Treated Liver	TCA Treated Liver
Heat Shock Protein 27KD	Golgi 4 Transmembrane Spanning Transporter	Insulin-Like Growth Factor-Binding Protein 2	Prothymosin alpha
Protein Kinase C theta	Protein Kinase C theta	Tob Antiproliferative Factor	
Rab-2 Ras Related Protein	Rab-2 Ras Related Protein	Heat Shock Protein 86	Heat Shock Protein 86
Rac 1 Murine Homologue	Rac 1 Murine Homologue	Erp72 ER Stress Protein	Erp72 ER Stress Protein
Glutathione S-Transferase A	Glutathione S-Transferase A	Etoposide Induced p53-Responsive mRNA	Etoposide Induced p53-Responsive (E124)mRNA
Glutathione S-Transferase Mu 1	Glutathione S-Transferase Mu 1	Glucose-Regulated Protein 78KD	Glucose-Regulated Protein 78KD
Nuclear Factor Related to NF-E2	Nuclear Factor Related to NF-E2	Oxidative Stress-Induced Protein	Oxidative Stress-Induced Protein
Split Hand/Foot Gene	Split Hand/Foot Gene	Inhibitor of RNA-Activated Protein Kinase 58KD	Inhibitor of RNA-Activated Protein Kinase 58KD
Integrin beta		Microsomal Glutathione S-Transferase	Microsomal Glutathione S-Transferase
CamK II Protein Kinase	CamK II Protein Kinase	Glutathione S-Transferase Pii	Glutathione S-Transferase Pii
CDC42 GTP-Binding Protein		Lymphocyte-Specific NGF Receptor Family Member CD27	Lymphocyte-Specific NGF Receptor Family Member CD27
Cytokeratin 18	Cytokeratin 18	Apolipoprotein J (Clusterin)	Apolipoprotein J (Clusterin)
		DAD-1; Defender against Cell Death 1	DAD-1; Defender against Cell Death 1
		TDAG51	
		PAC Stromal Protein (RAG1 Gene Activator)	
		MHR23B; Rad23 Homologue	
		Butyrate Response Factor I	
		Transcription Factor S-II	Transcription Factor S-II
		C5A Receptor	C5A-Receptor
		Bone Morphogenetic Protein 1	Bone Morphogenetic Protein 1
		Insulin-Like Growth Factor-Binding Protein 4	Insulin-Like Growth Factor-Binding Protein 4
		Neuroleukin	
		Cathepsin H	Cathepsin H
		Cathepsin L	Cathepsin L

CLAIMS

1. An assay for early detection of carcinogenesis, comprising the steps of:
 - a) preparing cDNA from RNA isolated from mammalian cells treated
5 with a test agent for less than about two years, wherein said cDNA is detectably labeled;
 - b) determining a pattern of expression by assessing the ability of said labeled cDNA to hybridize to each of a multiplicity of nucleotide sequences arrayed on a substrate;
 - 10 c) determining reference patterns of differential gene expression by assessing the ability of a second labeled cDNA to hybridize to each of a multiplicity of nucleotide sequences, wherein said second labeled cDNA is prepared from RNA isolated from mammalian cells treated with a known carcinogen for less than about two years and
 - 15 d) comparing similarities in patterns of expression from cells treated with a test agent to reference patterns from cells treated with a known carcinogen.
2. The assay of claim 1, wherein RNA is isolated from mammalian cells treated with a test agent or known carcinogen for less than about six months.
20
3. The assay of claim 2, wherein RNA is isolated from mammalian cells treated with a test agent or known carcinogen for less than about two weeks.
4. The assay of claim 3, wherein RNA is isolated from mammalian cells
25 treated with a test agent or known carcinogen for less than about two days.
5. The assay of claim 1, wherein said mammalian cells are treated *in vitro*.
- 30 6. The assay of claim 1, wherein said mammalian cells are treated *in vivo*.

7. The assay of claim 1, wherein said substrate is selected from the group consisting of: membrane filter; glass; ceramic; and solid organic polymer.

8. The assay of claim 1, wherein said detectable label is selected from the group consisting of: radioisotope; fluorescent dye molecule; enzyme; antigen or antibody.

9. The assay of claim 1, wherein said differential gene expression is selected from the group consisting of: genes whose level of expression is increased; genes whose level of expression is decreased; gene that are expressed; and genes that are not expressed.

10. A method to identify a test substance as a carcinogen, which method comprises:

- a) providing cDNA derived from mammalian cells that have been contacted with said test substance for less than about two years,
- b) determining a first pattern of hybridization of said cDNA with respect to a multiplicity of nucleotide sequences;
- c) comparing said pattern with a corresponding second pattern obtained at a corresponding time after said cells have been contacted with a known carcinogen, whereby a similarity in said first and second patterns identifies the test substance as a carcinogen.

11. The method of claim 10, wherein cDNA is obtained from said cells that have been contacted with said test substance or known carcinogen for less than about six months.

12. The method of claim 11, wherein cDNA is obtained from said cells that have been contacted with said test substance or known carcinogen for less than about two weeks.

13. The method of claim 12, wherein cDNA is obtained from said cells that have been contacted with said test substance or known carcinogen for less than about two days.

5 14. The method of claim 10, wherein said cells are contacted with a test substance or a known carcinogen *in vitro*.

15 15. The method of claim 10, wherein said cells are contacted with a test substance or a known carcinogen *in vivo*.

10

16 An assay for early detection of carcinogenesis, comprising the steps of:

a) selecting protein isolated from mammalian cells treated with a test agent for less than about two years;

15 b) measuring differences in protein synthesis or post-translational modification; and

c) determining whether said test agent is carcinogenic by comparing differences in protein synthesis or post-translational modification to protein isolated from mammalian cells treated with a known carcinogen for less than about two years.

20 17. The method of claim 16, wherein said differences in protein synthesis or post-translational modification are measured by electrophoretic gel analysis and said protein is detectably labeled.

25 18. The method of claim 16, wherein said differences in protein synthesis or post-translational modification are measured by enzymatic digestion of protein and mass spectrometry analysis.

19. The method of claim 16, wherein said protein is isolated from said cells treated with a test agent or known carcinogen for less than about six months.

30

20. The method of claim 19, wherein said protein is isolated from said cells treated with a test agent or known carcinogen for less than about two weeks.

21. The method of claim 20, wherein said protein is isolated from said cells treated with a test agent or known carcinogen for less than about two days.

5 22. The method of claim 16, wherein said cells are treated with a test substance or a known carcinogen *in vitro*.

23. The method of claim 16, wherein said cells are treated with a test substance or a known carcinogen *in vivo*.

10

24. Protein measured by any one of claims 16 to 23.

25. DNA used in any one of claims 1 to 15 that is predictive that a test agent or test substance is a carcinogen.

15

26. An assay kit for identifying a test substance as a carcinogen, comprising:

- a) reagents for the preparation of cDNA prepared from RNA isolated from mammalian cells treated with a test substance for less than about two years;
- 20 b) reagents for the preparation of cDNA prepared from RNA isolated from mammalian cells treated with a known carcinogen for less than about two years;
- c) DNA sequences arrayed on a substrate that are hybridizable to said cDNA; and
- d) label suitable for the detection of said DNA sequences hybridized to
- 25 said cDNA;

wherein said identification of a test substance as a carcinogen is achieved by creating a first pattern of differential gene expression using cDNA prepared from said RNA isolated from mammalian cells treated with a test substance for less than about two years and comparing said first pattern with a corresponding second pattern

30 obtained at a corresponding time after said cells have been contacted with a known carcinogen, whereby a similarity in said first and second patterns identifies the test substance as a carcinogen.




Figure 1

2 / 2
Figure 2

P-Primers

P1: 5'-ATTAACCCTCACTAAATGCTGGGGA-3'
P2: 5'-ATTAACCCTCACTAAATCGGTCATAG-3'
P3: 5'-ATTAACCCTCACTAAATGCTGGTGG-3'
P4: 5'-ATTAACCCTCACTAAATGCTGGTAG-3'
P5: 5'-ATTAACCCTCACTAAAGATCTGACTG-3'
P6: 5'-ATTAACCCTCACTAAATGCTGGGTG-3'
P7: 5'-ATTAACCCTCACTAAATGCTGTATG-3'
P8: 5'-ATTAACCCTCACTAAATGGAGCTGG-3'
P9: 5'-ATTAACCCTCACTAAATGTGGCAGG-3'
P10: 5'-ATTAACCCTCACTAAAGCACCGTCC-3'

T-Primers

T1: 5'-CATTATGCTGAGTGATATCTTTTTTTTAA-3'
T2: 5'-CATTATGCTGAGTGATATCTTTTTTTTAC-3'
T3: 5'-CATTATGCTGAGTGATATCTTTTTTTTAG-3'
T4: 5'-CATTATGCTGAGTGATATCTTTTTTTTCA-3'
T5: 5'-CATTATGCTGAGTGATATCTTTTTTTTCC-3'
T6: 5'-CATTATGCTGAGTGATATCTTTTTTTTCG-3'
T7: 5'-CATTATGCTGAGTGATATCTTTTTTTTGA-3'
T8: 5'-CATTATGCTGAGTGATATCTTTTTTTTGC-3'
T9: 5'-CATTATGCTGAGTGATATCTTTTTTTTGG-3'

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/23579

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	LU J ET AL: "Gene expression changes associated with chemically induced rat mammary carcinogenesis" MOLECULAR CARCINOGENESIS, vol. 20, no. 2, October 1997 (1997-10), pages 204-15, XP000900044 see abstract	1-15,26
Y	JACOBSON-KRAM D: "Carcinogenicity testing in the future" ENVIROMENTAL AND MOLECULAR MUTAGENESIS, vol. 31, no. suppl 29, 21 - 26 March 1998, page 17 XP000892339 see abstract T45	1-15,26
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

21 March 2000

Date of mailing of the international search report

28/03/2000

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Osborne, H

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/23579

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 27317 A (CHEE MARK ;LAI CHAOQIANG (US); LEE DANNY (US); AFFYMETRIX INC (US)) 31 July 1997 (1997-07-31) page 22, line 13 -page 23, line 15; claims 1,13,24,26 ---	1-15,26
A	FODOR S P A: "Massively parallel genomics" SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 277, no. 277, 18 July 1997 (1997-07-18), pages 393,395-395, XP002101908 ISSN: 0036-8075 the whole document ---	1-15,26
Y	FINCH J ET AL: "Identification of a cloned sequence activated during multi-stage carcinogenesis in mouse skin" CARCINOGENESIS,XX,XX, vol. 12, no. 8, August 1991 (1991-08), pages 1519-1522-1522, XP002112604 the whole document ---	1-15,26
A	WO 98 38329 A (HARTWELL LELAND ;FRIEND STEPHEN H (US); HUTCHINSON FRED CANCER RES) 3 September 1998 (1998-09-03) page 13, line 30 -page 17, line 23 page 3, paragraph 1 ---	16-23
A	WO 97 13877 A (LYNX THERAPEUTICS INC ;MARTIN DAVID W (US)) 17 April 1997 (1997-04-17) the whole document ---	1-15,26
P,X	WO 99 37817 A (SCHERING AG ;JOHNSON PAUL H (US); PONTE PHYLLIS A (US); ZAJCHOWSKI) 29 July 1999 (1999-07-29) page 3, line 21 - line 6 page 51, line 27 -page 52, line 12 ---	1-15,26
P,X	WO 99 27090 A (MORGAN GWYN ;BERTRAM TIMOTHY (GB); BUGELSKI PETER (GB); ENGLAND PA) 3 June 1999 (1999-06-03) claims 1,13 ---	1-15,26
P,X	WO 99 32660 A (AFFYMETRIX ;HO MING HSUI (US); WODICKA LISA (US); LOCKHART DAVID J) 1 July 1999 (1999-07-01) claim 72 -----	1-15,26

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 23579

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 24, 25
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 24 25

The subject matter of claims 24 and 25 respectively relate to protein and DNA per se. Since the technical features of the said claimed protein and said claimed DNA are not detailed, these claimed subject matter for which protection is being sought is undefined and thus unclear. As such claims 24 and 25 do not meet the clarity requirements of Art 6 PCT, and no meaningful search of these claimed subject matter could be undertaken.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/23579

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9727317 A	31-07-1997	AU 2253397 A EP 0880598 A	20-08-1997 02-12-1998
WO 9838329 A	03-09-1998	AU 6442398 A EP 0981640 A	18-09-1998 01-03-2000
WO 9713877 A	17-04-1997	AU 712929 B AU 4277896 A AU 6102096 A AU 7717596 A CN 1193357 A CZ 9700866 A CZ 9703926 A EP 0793718 A EP 0832287 A EP 0931165 A FI 971473 A HU 9900910 A JP 11507528 T JP 10507357 T NO 971644 A NO 975744 A PL 324000 A WO 9641011 A	18-11-1999 06-05-1996 30-12-1996 30-04-1997 16-09-1998 17-09-1997 17-06-1998 10-09-1997 01-04-1998 28-07-1999 04-06-1997 28-07-1999 06-07-1999 21-07-1998 02-06-1997 05-02-1998 27-04-1998 19-12-1996
WO 9937817 A	29-07-1999	AU 2341999 A	09-08-1999
WO 9927090 A	03-06-1999	AU 1166199 A	15-06-1999
WO 9932660 A	01-07-1999	AU 1926899 A	12-07-1999